SCHEMBL6736049

SCHEMBL6736049

O=C(Cl)c1ccc([N+](=O)[O-])s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.51
LMNA P02545 6/20 0.50
HTT P42858 5/20 0.50
RAB9A P51151 2/20 0.50
MAPT P10636 5/20 0.49
KMT2A Q03164 4/20 0.48
TP53 P04637 1/20 0.48
ATM Q13315 1/20 0.48
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 1/20 0.44
POLB P06746 1/20 0.44
CASP3 P42574 1/20 0.44
CASP7 P55210 1/20 0.44
CASP9 P55211 1/20 0.44
CASP6 P55212 1/20 0.44
CASP8 Q14790 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL28623908 0.94 SMN1; SMN2 (0.48) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL218867 0.82 SMN1; SMN2 (0.53) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL1937600 0.80 LMNA (0.54) SMN1; SMN2LMNAHTTRAB9AMAPT
Hydrochloric Acid SCHEMBL7036575 0.80 SMN1; SMN2 (0.51) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL2118284 0.80 ATM (0.55) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL23529356 0.80 SMN1; SMN2 (0.53) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL23561312 0.76 LMNA (0.48) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL6261682 0.76 SMN1; SMN2 (0.59) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL3268354 0.76 SMN1; SMN2 (0.61) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL28774615 0.76 LMNA (0.48) SMN1; SMN2LMNAHTTRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109280044-B Raltitrexed impurity C and preparation and application thereof 南京正大天晴制药有限公司 2021-04-02 CN claimed
US-20260125356-A1 TREATMENT OF LEISHMANIASIS THE UNIV OF DURHAM (GB) 2026-05-07 US disclosed
EP-4605086-A1 TREATMENT OF LEISHMANIASIS The University of Durham (GB) 2025-08-27 EP disclosed
CN-114667282-B Pyrimidine amide compounds and methods of treating cancer 昊运股份有限公司 2024-09-03 CN disclosed
US-20240150356-A1 Pyrimidine amide compounds and use thereof ALPHALA CO., LTD. (TW) 2024-05-09 US disclosed
WO-2024084186-A1 TREATMENT OF LEISHMANIASIS THE UNIVERSITY OF DURHAM (GB) 2024-04-25 WO disclosed
WO-2023244430-A1 PYRIMIDINE AMIDE COMPOUNDS AND USE THEREOF ALPHALA CO., LTD. (TW) 2023-12-21 WO disclosed
EP-4048656-A1 PYRIMIDINE AMIDE COMPOUNDS AND USE THEREOF Alphala Co., Ltd. (TW) 2022-08-31 EP disclosed
CN-114667282-A Pyrimidine amide compounds and methods of treating cancer 昊运股份有限公司 2022-06-24 CN disclosed
WO-2021080980-A1 PYRIMIDINE AMIDE COMPOUNDS AND USE THEREOF ALPHALA CO., LTD. (TW) 2021-04-29 WO disclosed
EP-0204529-B1 ANTI-CANCER QUINAZOLINE DERIVATIVES BTG INTERNATIONAL LIMITED (GB) 1993-03-31 EP disclosed
US-5187167-A Antitumor agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-16 US disclosed
US-5081124-A Amino acid and polyamino acid derivatives, inhibitors of thymidylate synthetase IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-01-14 US disclosed
EP-0239362-B1 ANTI-TUMOR AGENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-12-04 EP disclosed
US-4767758-A RADIOSENSITIZING CELLS; BLOCKING REACTION OF OXYGEN RADICALS CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1988-08-30 US disclosed
EP-0204529-A2 Anti-cancer quinazoline derivatives BTG INTERNATIONAL LIMITED (GB) 1986-12-10 EP disclosed
EP-0186252-A2 Use of thiophene compounds for the manufacture of a medicament against tumours CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1986-07-02 EP disclosed
US-4061851-A 7-Amino-7-arylthio cephalosporins E. R. SQUIBB & SONS, INC. (US) 1977-12-06 US disclosed
US-4026886-A 7-Acyl-7-arylthiocephalosporins E. R. SQUIBB & SONS, INC. (US) 1977-05-31 US disclosed
US-3954744-A ANTIBACTERIAL E. R. SQUIBB & SONS, INC. (US) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125356-A1 TREATMENT OF LEISHMANIASIS NR1H2, NR1H3, MSR1 SMN1; SMN2 1833/4885LMNA 1064/4885HTT 4861/4885
US-20240150356-A1 Pyrimidine amide compounds and use thereof TYMP, DPYD, TYMS SMN1; SMN2 1301/4885LMNA 3275/4885HTT 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.